24.81
+0.15(+0.61%)
Currency In USD
| Previous Close | 24.66 |
| Open | 25.01 |
| Day High | 25.75 |
| Day Low | 24.15 |
| 52-Week High | 27.55 |
| 52-Week Low | 13.36 |
| Volume | 139,955.02 |
| Average Volume | 229,501 |
| Market Cap | 631.97M |
| PE | -7.98 |
| EPS | -3.13 |
| Moving Average 50 Days | 23.68 |
| Moving Average 200 Days | 19.76 |
| Change | 0.32 |
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug developmentNEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company de
LB Pharmaceuticals to Participate in Upcoming March Investor Events
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatmen
LB Pharmaceuticals Announces $100.0 Million Private Placement
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsych